Clareo Health | Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)
Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tetherex Pharmaceuticals Corporation
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Part 1:
Males or females, 18-65 years of age (inclusive)
Body Mass Index (BMI) ≥ 18.0 and ≤ 35.0 kg/m2
Documented physician-diagnosed asthma for ≥ 4 months prior to screening
Pre-bronchodilator FEV1 ≥ 70% predicted at screening
Documented allergy to at least one common allergen as confirmed by the skin prick test
Dual responder to inhaled bronchial allergen challenges as manifested by positive allergen-induced early (EAR) and late airway bronchoconstriction (LAR) at screening
Male or female, 40 to 75 years of age, inclusive, at the time of informed consent.
Confirmed diagnosis by a physician of COPD with symptoms compatible with COPD for at least 1 year prior to screening.
BMI ≥ 18.0 and ≤ 35.0 kg/m2 at screening.
Able to tolerate sputum induction and produce an adequate sputum sample with a neutrophil differential count \> 55% at screening.
Post-bronchodilator FEV1 ≥ 30% and ≤ 80% of the predicted normal, and post-bronchodilator FEV1/FVC \< 0.7 at the time of Screening.
Current or former tobacco smoker who has a smoking history of at least 10 pack years (Ten pack- years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years).
Has a negative result in the blood test for tuberculosis (TB) at screening.
You may not be if
Lung disease other than stable, mild asthma; e.g., worsening of asthma that requires a change in asthma therapy in the past 4 weeks or is deemed clinically significant by the investigator.
A diagnosed current or recent (within previous 8 weeks of screening, or prior to randomisation) bacterial, protozoal, viral or parasitic infection; is suspected of or is at high risk of having a parasitic infection, or has a history of more than one episode of herpes zoster infection.
Has a history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest and/or hypoxic seizures.
Has been hospitalised or has attended the emergency room for asthma in the 12 months prior to screening, or prior to randomisation.
A history of tuberculosis (latent or active) or systemic fungal diseases.
Part 2:
COPD exacerbation requiring oral steroids and/or antibiotics, within the 8 weeks prior to screening or prior to randomisation.
A positive sputum culture at Screening indicating ongoing infection.
Other respiratory disorders: Subjects with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, known alpha-1 antitrypsin deficiency or other active pulmonary diseases other than COPD.
A history of life-threatening COPD including intensive care unit admission and/or requiring intubation within the last 5 years.
A history of \> 1 hospitalisation for COPD in the previous 1 year prior to screening.
Previous lung resection, lung reduction surgery or lung transplantation.
Requires supplemental oxygen, even on an occasional basis.
Any infection requiring hospitalisation or intravenous antibiotics within 6 months prior to Screening or prior to randomisation.
A diagnosed current or recent (within previous 8 weeks of screening, or prior to randomisation) bacterial, protozoal, viral or parasitic infection; is suspected of or is at high risk of having a parasitic infection, or has a history of more than one episode of herpes zoster infection.
Active participation in a pulmonary rehabilitation program.
A history of tuberculosis (latent or active) or systemic fungal diseases.
